Prion Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Prion [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of rare, invariably fatal neurodegenerative disorders caused by the misfolding and self-propagation of the cellular [prion protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein--TEMP--/proteins)--FIX-- (PrP^C) into an abnormal, protease-resistant isoform (PrP^Sc). This paradigm-shifting concept, established by Stanley Prusiner's Nobel Prize-winning work, demonstrated that a protein alone — without nucleic acids — can act as an infectious agent (Prusiner, 1998). Prion diseases affect both humans and animals and are characterized by spongiform degeneration of the brain, progressive [neuronal] loss, and [astrocytic] gliosis. Despite decades of research, no effective [treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/treatments exist, making these disorders among the most devastating in neurology.
The normal cellular prion protein PrP^C is encoded by the PRNP gene on chromosome 20p13 and is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on the surface of [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, and other cells throughout the body (Aguzzi et al., 2008). PrP^C has a predominantly alpha-helical structure and is involved in:
- Copper binding and [metal homeostasis]: PrP^C binds copper ions via its N-terminal octapeptide repeat region
- [Neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection--TEMP--/treatments)--FIX--: Anti-apoptotic and anti-oxidant functions protecting [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- against [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- damage
- Synaptic signaling: Modulation of [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] activity, synaptic plasticity, and neurotransmitter release
- Myelin maintenance: Interaction with neuronal cell adhesion molecules
- Cell adhesion: Binding to laminin, neural cell adhesion molecule (NCAM), and other extracellular matrix components
The central event in Prion Disease is the conformational conversion of PrP^C into PrP^Sc, involving a profound shift from an alpha-helix-rich structure to one dominated by beta-sheet motifs. PrP^Sc has several distinctive properties (Caughey & Lansbury, 2003):
- Protease resistance: Partially resistant to proteinase K digestion (the diagnostic hallmark)
- Self-templating: PrP^Sc acts as a template, inducing PrP^C to adopt the misfolded conformation in an autocatalytic cascade
- Aggregation: Forms amyloid fibrils and plaques
- Insolubility: Resistant to standard detergents and denaturants
- Strain diversity: Different conformations of PrP^Sc produce distinct disease phenotypes (prion strains)
Recent biophysical studies have revealed that PrP is not merely a static monomer but a dynamic scaffold capable of liquid-liquid phase separation (LLPS), adding complexity to our understanding of the conversion process (Prion 2025 Conference).
The mechanisms by which PrP^Sc causes neuronal death remain incompletely understood but involve multiple pathways:
- [unfolded protein response[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- ([UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- activation: PrP^Sc accumulation triggers [endoplasmic reticulum stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- and chronic [UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- activation, leading to translational repression and neuronal death
- [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--: Increased [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production and impaired antioxidant defenses
- Synaptic dysfunction: Early synaptic loss precedes neuronal death; impairment of [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] signaling and neurotransmitter release
- **[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/Brown et al., 2000https://doi.org/10.1212/WNL.55.8.1075)).
- Variant CJD (vCJD): Linked to BSE-contaminated beef; median age 28 years; prominent psychiatric symptoms; 12-14 month duration (Will et al., 1996).
FFI is a rare hereditary Prion Disease caused by the D178N mutation in PRNP with methionine at codon 129 on the mutant allele. It is characterized by progressive untreatable insomnia, dysautonomia, motor dysfunction, and cognitive decline. The [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX-- is preferentially affected, with severe neuronal loss in the anterior and dorsomedial thalamic nuclei. Median survival is 12-18 months. Sporadic fatal insomnia (SFI) presents similarly but without PRNP mutations.
GSS is a rare autosomal dominant Prion Disease caused by various PRNP mutations (most commonly P102L). It presents in mid-life with progressive cerebellar ataxia, followed by dementia. Disease duration is typically longer than CJD (2-10 years). Neuropathologically, GSS is characterized by multicentric PrP amyloid plaques in the [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- and cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--.
[Kuru[/diseases/[kuru[/diseases/[kuru[/diseases/[kuru[/diseases/[kuru--TEMP--/diseases)--FIX-- was endemic among the Fore people of Papua New Guinea and was transmitted through ritualistic endocannibalism. It represents one of the first recognized human prion diseases and provided key evidence for the transmissibility of spongiform encephalopathies (Collins et al., 2004). The cessation of cannibalistic practices in the 1950s led to its near-elimination, though cases with incubation periods exceeding 50 years have been documented, highlighting the extraordinary latency possible with prion infections.
VPSPr is a recently described sporadic Prion Disease with unique biochemical properties: the misfolded PrP shows variable sensitivity to protease digestion. It typically presents with psychiatric symptoms, speech difficulties, and cognitive decline, with a longer disease course than sCJD.
BSE ("mad cow disease") caused a major epidemic in UK cattle during the 1980s-1990s, with over 180,000 confirmed cases. The BSE crisis prompted massive changes in food safety regulation after the discovery that BSE prions could cross the species barrier to cause vCJD in humans (Will et al., 1996).
CWD affects cervids (deer, elk, moose, reindeer) across North America, Scandinavia, and South Korea. It is the most efficiently transmissible Prion Disease known, with horizontal transmission through saliva, urine, feces, and environmental contamination. No human cases have been definitively linked to CWD, but the potential for zoonotic transmission remains a public health concern.
Scrapie in sheep and goats is the oldest known Prion Disease, first described in the 18th century. It served as the experimental model for much of the foundational prion research and continues to be important for understanding prion biology.
Diagnosis of Prion Disease involves a combination of clinical assessment, [neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging--TEMP--/diagnostics)--FIX--, and laboratory testing (Zerr et al., 2009):
The WHO and updated diagnostic criteria classify CJD as definite (neuropathological confirmation), probable, or possible based on:
- Progressive dementia with characteristic neurological signs (myoclonus, cerebellar ataxia, visual/pyramidal/extrapyramidal signs, akinetic mutism)
- Supportive investigations (EEG, MRI, CSF biomarkers)
- MRI Brain: Diffusion-weighted imaging (DWI) showing cortical ribboning and/or [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- hyperintensity is highly sensitive (~92%) and specific (~95%) for sCJD
- Real-Time Quaking-Induced Conversion (RT-QuIC): Ultrasensitive assay detecting PrP^Sc seeding activity in CSF (sensitivity ~92%, specificity ~100%). Can now be performed on nasal brushings and skin biopsies
- CSF biomarkers: 14-3-3 protein (sensitive but nonspecific), total tau] (markedly elevated), [neurofilament light chain[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein--TEMP--/proteins)--FIX-- ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--
- EEG: Periodic sharp wave complexes (PSWC) in 60-80% of sCJD cases
- PRNP gene sequencing: Essential for familial forms and codon 129 genotyping
- Neuropathological examination: Gold standard; demonstrates spongiform change, [neuronal] loss, gliosis, and PrP^Sc immunostaining
¶ Treatment and Therapeutic Development
¶ Current Standard of Care
There is currently no cure or disease-modifying treatment for any Prion Disease. Management is entirely supportive and palliative:
- Myoclonus: Clonazepam, valproic acid
- Seizures: Antiepileptic medications
- Pain: Standard analgesic protocols, opioids as needed
- Psychiatric symptoms: Cautious use of antipsychotics and anxiolytics
- Nutritional support and swallowing management
- Family counseling and end-of-life care
Despite the current lack of treatments, several strategies show preclinical promise:
PrP^C Reduction (Most Promising)
Antisense oligonucleotides (ASOs) targeting PRNP mRNA represent the most advanced therapeutic strategy. In animal models, ASO-mediated PrP^C knockdown extended survival by up to 98% when administered prophylactically. Clinical trials are being planned for human Prion Disease (Raymond et al., 2019).
[Immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX--
Anti-PrP antibodies and active vaccination approaches:
- Modified PrP peptide vaccines (PrP131-150, PrP211-230) elicited immune responses in mice and delayed scrapie
- Passive immunotherapy with anti-PrP monoclonal antibodies showed efficacy in cell culture
- Challenge: PrP^Sc in the CNS is poorly accessible to peripheral antibodies due to the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--
Small Molecule Approaches
- Efavirenz (FDA-approved anti-HIV drug) reduced PrP^Sc and extended survival in scrapie-infected mice by regulating [brain cholesterol metabolism] (JCI Insight, 2024)
- Novel porphyrins (Zn(II)-BnPyP) targeting PrP^C with bimodal mechanism of action
- Anle138b: Oligomer modulator that showed promise in animal models
- Doxycycline: Extended survival in some animal studies; [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials showed mixed results
[Gene Therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX--
CRISPR-based approaches for permanent PRNP silencing are in preclinical development.
| Feature |
Value |
| Incidence (sCJD) |
1-2 per million per year worldwide |
| US cases (annual) |
~350 |
| Mean age of onset (sCJD) |
60-65 years |
| Median age of onset (vCJD) |
28 years |
| Survival (sCJD) |
Median 4-6 months |
| Survival (vCJD) |
Median 12-14 months |
| Sex ratio |
Slight male predominance (1.2:1) |
| vCJD cases worldwide (cumulative) |
~230 (majority in UK) |
The National Prion Disease Pathology Surveillance Center (NPDPSC) at [Case Western Reserve University[/institutions/[case-western[/institutions/[case-western[/institutions/[case-western[/institutions/[case-western--TEMP--/institutions)--FIX-- provides diagnostic support and surveillance for prion diseases in the United States.
Prevention strategies focus on limiting exposure:
- Surgical instrument decontamination: Standard autoclaving is insufficient for prion inactivation; specialized protocols using NaOH or NaOCl are required
- Blood supply safety: Leukoreduction and deferral of donors with potential BSE exposure
- Animal health surveillance: Monitoring for BSE in cattle and CWD in cervids
- Genetic counseling: For families with PRNP mutations
- Food safety regulations: Specified risk material (SRM) removal from the food chain
Current [research priorities[/[research-priorities[/[research-priorities[/[research-priorities[/[research-priorities[/[research-priorities[/[research-priorities[/[research-priorities[/research-priorities include (Bhatt et al., 2024):
- PrP^C reduction therapies: ASOs and gene silencing approaches entering clinical development
- Ultrasensitive [diagnostics[/[diagnostics[/[diagnostics[/[diagnostics[/[diagnostics[/[diagnostics[/[diagnostics[/[diagnostics[/diagnostics: Expanding RT-QuIC to skin, blood, and urine for early/pre-symptomatic detection
- Prion strain characterization: Understanding how different PrP^Sc conformations produce distinct disease phenotypes
- Phase separation biology: Investigating PrP's role in liquid-liquid phase separation and how this relates to pathological aggregation
- CWD zoonotic potential: Monitoring for evidence of human susceptibility to cervid prions
- Biomarker development: Blood-based assays for screening and early detection
The study of Prion Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--
- [Microglia[/Prion Protein ([PrP[/Prion Protein ([PrP[/Prion Protein ([PrP[/Prion Protein ([PrP[/Prion Protein ([PrP[/Prion Protein ([PrP[/Prion Protein ([PrP[/Prion Protein ([PrP](/Prion Protein (PrP)[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein--TEMP--/proteins)--FIX--)
- [Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95(23):13363-13383. DOI
- [Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet. 2004;363(9402):51-61. DOI
- [Aguzzi A, Baumann F, Bremer J. The prion's elusive reason for being. Annu Rev Neurosci. 2008;31:439-477. DOI
- [Geschwind MD. Prion diseases. Continuum. 2015;21(6):1612-1638. DOI
- [Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob Disease in the UK. Lancet. 1996;347(9006):921-925. DOI
- [Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob Disease at the millennium. Neurology. 2000;55(8):1075-1081. DOI
- [Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267-298. DOI
- [Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob Disease. Brain. 2009;132(10):2659-2668. DOI
- [Raymond GJ, Zhao HT, Race B, et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;4(16):e131175. DOI
- [Bhatt D, et al. Treatment with efavirenz extends survival in a Creutzfeldt-Jakob Disease model by regulating brain cholesterol metabolism. JCI Insight. 2024;9(22):e190296. DOI
- [Bhatt S, et al. New implications for prion diseases therapy and prophylaxis. Front Mol Neurosci. 2024;17:1324702. DOI
- [Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob Disease and other human spongiform encephalopathies. Brain Pathol. 1995;5(4):459-466. DOI
- [Mead S, Burnell M, Lowe J, et al. Clinical trial of quinacrine in human Prion Disease. Neurology. 2022;98(17):e1752-e1760. DOI
- [Prion 2024 Conference Abstracts. Prion. 2024;18(1):133-191. DOI
- National Prion Disease Pathology Surveillance Center. Case Western Reserve University. []https://case.edu/medicine/pathology/divisions/npdpsc]https://case.edu/medicine/pathology/divisions/national-prion-disease-pathology-surveillance-center/